跳至主要内容
临床试验/NCT00002139
NCT00002139已完成1 期

Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.

Pfizer1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
试验地点
1

研究概览

简要总结

To compare the uptake of azithromycin in white cells relative to plasma concentrations in HIV-infected patients.

详细描述

Patients are randomized to receive azithromycin orally or intravenously, with crossover to the alternate treatment after a 21-day wash-out period.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •Antiretroviral agents, provided regimen has been stable for at least 1 month.
  • •Patients must have:
  • •HIV infection.
  • •CD4 count <= 200 cells/mm
  • •No active opportunistic infection (pending discussion with Pfizer Clinician).
  • •Prior Medication:
  • •Prior antiretroviral agents.

排除标准

  • •Co-existing Condition:
  • •Patients with the following symptoms or conditions are excluded:
  • •Active intercurrent illness (pending discussion with the Pfizer Clinician).
  • •Allergies to macrolide antibiotics.
  • •Signs and symptoms of severe illness that would preclude treatment.
  • •Patients with the following prior conditions are excluded:
  • •History of clinically significant allergic, hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease.
  • •Clinically important change in baseline status within 4 weeks prior to study entry.
  • •Condition affecting drug absorption (e.g., ulcers, gastrectomy, HIV-associated enteropathies) within 4 weeks prior to study entry.
  • •Prior Medication:
  • •Investigational drugs including treatment IND drugs within 4 weeks prior to study entry.
  • •Known drug or alcohol dependence.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验